These independent CME/CE activities are supported by educational grants from

Bristol-Myers Squibb and ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company

Genentech BioOncology

Sanofi-Aventis U.S.
The Certificate Program in
Advanced/Metastatic Colorectal Cancer
  1. Course List
Chair
faculty image
Leonard B. Saltz, MD
  • Professor of Medicine
  • Weill Medical College of Cornell University
  • Attending Physician
  • Memorial Sloan Kettering Cancer Center
  • New York, New York
    • Featuring the most up-to-date information available about diagnostic methods used to screen for advanced/metastatic colorectal cancer, practice guidelines, and current and emerging treatment strategies.
  • Determine the importance of environmental, dietary, and hereditary risk factors associated with the development of colorectal cancer.
  • Analyze the guidelines/recommendations and options for treatment of patients with stage two and stage three colon and rectal cancer.
  • Assess the first-line and subsequent treatment options available for patients with metastatic colorectal cancer.
  • Evaluate the options available for multimodal management of patients with resectable metastatic colorectal cancer.

    • Chemotherapy Regimens

    • 5-fluorouridine (5-FU)
    • Leucovorin (LV)
    • Oxaliplatin
    • Capecitabine
    • Irinotecan
    • FOLFOX (oxaliplatin plus LV plus 5-FU)
    • CapeOX (oxaliplatin plus capecitabine)
    • FOLFIRI (irinotecan plus LV plus 5-FU)
    • LV plus 5-FU

    Monoclonal Antibodies

    • Cetuximab
    • Panitumumab
    • Bevacizumab

    Additional Agents

    • Dasatinib
    • Cediranib
    • Nilotinib
    • ABT 869
    • Aflibercept
    • Epidemiology
    • Early screening
    • Choosing regimens
    • First-, second-, and third-line treatments
    • Targeted therapy

    Target Audience

    These activities are designed for medical oncologists, gastrointestinal oncologists, and other clinicians involved in the care of patients with advanced/metastatic colorectal cancer.

     

    Activity Goal

    The goals of these CME/CE activities are to:

    • Describe state-of-the-science methods for evaluating and selecting treatments for patients with stage two and stage three colon and rectal cancers.
    • Select interventions to optimize outcomes for patients with metastatic colorectal cancer.